JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on SION stock, giving a Buy rating on November 5.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on several promising developments and strategic advancements by Sionna Therapeutics. The company has made significant progress with its NBD1 stabilization approach for cystic fibrosis, particularly with the SION-719 advancement to Phase 2 trials. This progress has led to an increased price target of $52, reflecting confidence in the potential efficacy and safety outcomes expected in mid-2026.
Furthermore, Sionna’s proprietary combination programs, including the ongoing Phase 1 trial of SION-451 in Australia, demonstrate a robust pipeline. The clearance of the IND application by the FDA further supports the advancement of these programs. Additionally, Sionna’s strong cash position of approximately $325 million provides a solid financial foundation to support its ongoing research and development efforts.
In another report released on November 5, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SION in relation to earlier this year.